Selective radiosensitization of p53–deficient cells by caffeine–mediated activation of p34cdc2 kinase

The induction of tumor cell death by anticancer therapy results from a genetic program of autonomous cell death termed apoptosis. Because the p53 tumor suppressor gene is a critical component for induction of apoptosis in response to DNA damage, its inactivation in cancers may be responsible for the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature medicine 1996-10, Vol.2 (10), p.1140-1143
Hauptverfasser: Yao, Siu-Long, Akhtar, Adil J., Mckenna, Karen A., Bedi, Gauri C., Sidransky, David, Mabry, Mack, Ravi, Rajani, Collector, Michael I., Jones, Richard J., Sharkis, Saul J., Fuchs, Ephraim J., Bedi, Atul
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The induction of tumor cell death by anticancer therapy results from a genetic program of autonomous cell death termed apoptosis. Because the p53 tumor suppressor gene is a critical component for induction of apoptosis in response to DNA damage, its inactivation in cancers may be responsible for their resistance to genotoxic anticancer agents. The cellular response to DNA damage involves a cell–cycle arrest at both the G 1 /S and G 2 /M transitions; these checkpoints maintain viability by preventing the replication or segregation of damaged DNA. The arrest at the G 1 checkpoint is mediated by p53–dependent induction of p21 WAFI/ClP1 , whereas the G 2 arrest involves inactivation of p34 cdc2 kinase. Following DNA damage, p53–deficient cells fail to arrest at G 1 and accumulate at the G 2 /M transition. We demonstrate that abrogation of G 2 arrest by caffeine–mediated activation of p34 cdc2 kinase results in the selective sensitization of p53–deficient primary and tumor cells to irradiation–induced apoptosis. These data suggest that pharmacologic activation of p34 cdc2 kinase may be a useful therapeutic strategy for circumventing the resistance of p53–deficient cancers to genotoxic anticancer agents.
ISSN:1078-8956
1546-170X
DOI:10.1038/nm1096-1140